BACTERIAL POLYSACCHARIDE CROSS-REACTIVE WITH MENINGOCOCCAL GROUP A POLYSACCHARIDE

类似于其他包裹的细菌病原体，抗包膜 多糖类抗体对奈瑟氏菌引起的疾病具有免疫力 脑膜炎。A组脑膜炎双球菌疾病有不同的流行病学 而不是其他致病血清群。在非洲，A组脑膜炎是 地方性高频率；在世界其他地区，A组引起 流行病。在这两种情况下，A组无症状携带 脑膜炎双球菌含量低。在美国，A组疾病或携带者 脑膜炎双球菌可以被认为是过去30年来没有的。然而，大多数 全世界的儿童和年轻人都有A组多糖 抗体。在调查中发现了交叉反应的多糖类 在非致病的正常菌群中可能解释了这种无处不在的 天然免疫，两种大肠杆菌衣壳多糖，K93和 K51，并对其血清学性质和结构进行了研究 特色化的。尽管它们具有抗原交叉反应，但K93和K51 免疫前、后血清A群抗体吸收失败 接种A组脑膜炎双球菌疫苗。重要的是 K93多糖中的0-乙酰基在这种交叉反应中 已经成立了。K93、K51和A族多糖的合成方案 具有医学用途的载体蛋白已经被设计出来，以便 准备用于临床评估的结合物。这样的产品应该更多 婴幼儿A组脑膜炎的有效免疫原 而不是A组疫苗。 一名患者，无恶性，且具有高水平的单抗 对B群脑膜炎双球菌和大肠杆菌K1囊膜均有反应 发现了多糖类化合物。血吸虫病的特异性和保护作用 对该单抗进行了鉴定。其治疗慢性阻塞性肺疾病的疗效观察 B组脑膜炎双球菌脑膜炎的治疗计划进行研究。

Similar to other encapsulated bacterial pathogens, anti-capsular polysaccharide antibodies confer immunity to diseases caused by Neisseria meningitidis. Group A meningococcal diseases have a different epidemiology than the other pathogenic serogroups. In Africa, Group A meningitis is endemic with high frequency; in other parts of the world, Group A causes epidemics. In both situations, asymptomatic carriage of Group A meningococci is low. In the U.S., disease or carriage of Group A meningococci can be considered as absent for the past 30 years. Yet, most children and young adults throughout the world have Group A polysaccharide antibodies. During investigations to find cross-reactive polysaccharides among non-pathogenic normal flora that might account for this ubiquitous "natural" immunity, two Escherichia coli capsular polysaccharides, K93 and K51, were discovered and their serological properties and structures characterized. Despite their antigenic cross-reactivity, the K93 and K51 failed to absorb Group A antibodies from pre and post immunization sera of vaccinates injected with Group A meningococcal vaccine. Importance of the 0-acetyl in the K93 polysaccharide in this cross-reactivity was established. Schemes for synthesis of K93, K51 and Group A polysaccharides with medically useful carrier proteins have been devised in order to prepare conjugates for clinical evaluation. Such products should be more effective immunogens against Group A meningitis in infants and children than Group A vaccine. A patient, without malignancy and with high levels of a monoclonal antibody reactive with both Group B meningococcal and E. coli K1 capsular polysaccharides, was discovered. The specificity and protective effects of this monoclonal antibody were characterized. Its therapeutic effect in the treatment of Group B meningococcal meningitis is planned to be studied.